DSIP 10mg

Research Overview

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) was first isolated in 1974 by the Schoenenberger-Monnier group at the University of Basel, Switzerland, from the cerebral venous blood of rabbits in electrically induced slow-wave sleep. DSIP-like immunoreactivity has since been detected in the hypothalamus, limbic system, pituitary gland, and human breast milk.[1][17]

DSIP remains neuroscience's "unresolved riddle": despite 50+ years of study, no specific gene coding for a DSIP precursor has been identified, and no dedicated receptor has been cloned. Sequence analysis suggests homology with the 324–332 fragment of human lysine-specific histone demethylase 3B (KND peptide, JMJD1B gene).[1]

Originally pursued as a "somnogenic molecule" to cure insomnia, the therapeutic rationale shifted to that of a "programming modulator" or adaptogen — stabilizing neuronal activity and restoring homeostasis under stress or disrupted circadian rhythms. Research spans 8+ indication categories across neurology, addiction medicine, oncology, cardiology, and gerontology.[9]

Discovery and historical context: The Schoenenberger-Monnier program at Basel pursued the "humoral hypothesis of sleep" — that a circulating factor accumulating during wakefulness drives the transition into slow-wave sleep. Cerebral venous blood from rabbits in electrically-induced thalamic-stimulated sleep was dialyzed and infused into recipient rabbits, reproducing the delta-EEG signature. The active fraction was isolated, sequenced as a linear nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, MW 848.81 Da), and synthesized — the synthetic preparation reproduced the EEG-modifying activity of the natural extract.[1][17]

Research framework: DSIP exhibits an unusual pharmacological profile that distinguishes it from receptor-targeted neuropeptides — bell-shaped dose-response, partial blood-brain-barrier penetration, ~15-min plasma half-life with rapid N-terminal tryptophan cleavage by aminopeptidases, and no cloned receptor. The aminopeptidase-resistant analog [D-Ala²]DSIP and the more-potent KND peptide (WKGGNASGE, single Asp→Asn substitution at position 5) are the standard structural tools used in modern preclinical studies to dissect the underlying signaling. Investigators studying related stress-modulating and neuroprotective peptides commonly cross-reference our Selank, Semax, and Epithalon pages for parallel adaptogen pharmacology and circadian-rhythm modulation in rodent models.[9]

Mechanism of Action

DSIP's exact mechanism remains partially obscure — the "unresolved riddle" stems from the absence of a cloned receptor or identified gene. However, extensive research characterizes its interactions across multiple receptor systems and signaling cascades.[1]

Receptor Targets

Downstream Signaling

Dose-Response: Bell-Shaped Curve

Key analog: KND peptide (WKGGNASGE) — differs by single amino acid (Asn vs Asp at position 5); more potent antioxidant; greater reduction in myocardial infarction (19.1% vs 28.7%).[8]

Integrative Model: "Programming Modulator"

The absence of a single high-affinity receptor — combined with documented modulatory activity at NMDA, opioid, α₁-adrenergic, MAPK, MAO-A, antioxidant-enzyme, c-Fos, and mitochondrial respiration endpoints — supports the Schoenenberger framework that DSIP acts as a state-dependent neuronal-tone stabilizer rather than a classical agonist or antagonist. Computational analyses propose homology with the 324-332 fragment of human lysine-specific histone demethylase 3B (JMJD1B), suggesting endogenous DSIP-like activity may arise from proteolytic cleavage of a larger precursor rather than from a dedicated DSIP gene.[1][9]

Pharmacokinetics & Delivery Constraints

The ~15-min plasma half-life — driven by N-terminal Trp cleavage by aminopeptidases — has shaped the design of the modern DSIP literature. Intracerebroventricular and intranasal routes bypass the high peripheral degradation rate and produce reproducible CNS effects at far lower doses than systemic administration; this asymmetry explains the wide spread in published "effective doses" (intracerebroventricular sub-µg ranges versus intraperitoneal mg-range protocols). The aminopeptidase-resistant analog [D-Ala²]DSIP and the KND analog were developed to address this constraint.[7][8]

Stress-Axis & HPA Modulation

In stress paradigms, DSIP prevents c-Fos induction in the paraventricular nucleus, lowers basal corticotropin output, and blocks cortisol release — effects that are reversible by NMDA-receptor agonists and by naloxone, implicating combined NMDA-modulation and opioid-receptor pathway as the mechanistic substrate. Sudakov 1983 and Salieva 1989 showed that systemic DSIP increased animal resistance to acute emotional stress, paralleling the antidepressant-like reduction in pain-and-depression scores observed in the Larbig 1984 chronic-pain pilot.[18][21]

Research Applications

DSIP research spans 8+ indication categories across neurology, addiction, oncology, and gerontology:

1. Sleep Regulation & Insomnia — Increases delta (slow-wave) sleep 39–54% in rabbits; 59% median increase in total sleep time in humans (25 nmol/kg IV); 7-night treatment normalized chronic insomnia.[3][4]
2. Withdrawal Syndrome Treatment — 97% improvement in opiate withdrawal (n=60); 87% in alcohol withdrawal (n=47); terminated delirium tremens in 6/8 cases.[2]
3. Stress Adaptation & HPA Modulation — Reduces stress-induced metabolic disorders; lowers basal corticotropin; blocks cortisol release; prevents c-fos expression during emotional stress.[18]
4. Pain Management — Dose-dependent antinociceptive effect (blocked by naloxone); reduced pain in 6/7 chronic pain subjects.[11][5]
5. Neuroprotection & Stroke Recovery — DSIP/KND reduced brain infarction volume during reperfusion; accelerated motor function recovery in focal stroke.[8][7]
6. Cardioprotection — Reduces myocardial infarction size (IA/AAR 28.7% vs 42.1% control); stabilizes mitochondrial respiration. ⚠️ 100% mortality if given during occlusion phase.[8]
7. Epilepsy & Anticonvulsant — In the metaphit audiogenic seizure model, DSIP alone did not significantly alter seizure latency, but potentiated the anticonvulsive activity of an otherwise non-protective valproate dose; intranigral DSIP and its analogs have also been studied for effects on movement and convulsive activity.[16][20]
8. Geroprotection & Oncology — Maximum lifespan +24.1% in SHR mice; total tumors ↓2.6-fold; mammary carcinoma ↓5-fold; chromosomal aberrations ↓22.6%.[10]
9. Mitochondrial & Antioxidant Research — Stabilizes NADH-dehydrogenase, enhances oxidative phosphorylation, stimulates SOD/catalase/glutathione peroxidase — used as a tool peptide for studying mitochondrial cytoprotection under hypoxic/ischemic stress.[9]
10. HPA Axis Stress Resistance — Prevents c-Fos induction in paraventricular nucleus, lowers basal corticotropin, increases resistance to acute emotional stress in rodent models (Sudakov 1983, Salieva 1989).[18][21]

Comparative Research Context

DSIP occupies a unique position in the adaptogen / programming-modulator literature alongside other stress-and-circadian-rhythm peptides such as Selank, Semax, Epithalon, and Pinealon. Where Selank acts via tuftsin-related immunomodulatory and anxiolytic pathways and Semax activates BDNF expression in the hippocampus, DSIP appears to operate through state-dependent stabilization of multiple receptor systems without a dedicated high-affinity target. Researchers comparing DSIP with related adaptogen peptides commonly cross-reference our Selank, Semax, and Epithalon pages for parallel preclinical pharmacology — particularly for studies addressing slow-wave sleep, oxidative stress resistance, and HPA-axis modulation in rodent models. The KND peptide and [D-Ala²]DSIP analogs remain the standard tools for distinguishing DSIP-specific effects from generic peptide vehicle effects in mechanism-of-action studies.

Preclinical Research Summary

Key Preclinical Studies

Clinical / Human Studies

Safety Summary